<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615938</url>
  </required_header>
  <id_info>
    <org_study_id>EudratCT:2013-003714-40</org_study_id>
    <nct_id>NCT02615938</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)</brief_title>
  <acronym>HCQ-chILD-EU</acronym>
  <official_title>Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Griese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled,
      parallel-group, multinational study investigating the initiation or withdrawal of
      hydroxychloroquine in subjects with chILD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an explorative, prospective, randomized, double-blind, placebo controlled
      investigation of hydroxychloroquine (HCQ) in pediatric ILD. The treatments are organized in
      START and STOP blocks, which can be initiated in sequence, as needed by the subjects. Each
      patient can participate in each block only once. In the START block subjects are randomized
      to parallel-groups, then the placebo group is switched to active drug. In the STOP block,
      subjects on HCQ are randomized into parallel-groups treated with placebo or HCQ to
      investigate the withdrawal of HCQ for assessment of its efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Oxygenation</measure>
    <time_frame>Start HCQ block: 28 and 56 days; Stop HCQ block: 84 days</time_frame>
    <description>Start HCQ block: relative Change Trial day 1 through day 28 and relative Change day 28 to day 56; Change active compound compared to Change Placebo.
Stop HCQ block: Relative change trail day 1 through day 84: change active compound compared to change Placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Oxygen Saturation</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(O2-sat, in room air) (only absolute, as relative already Primary outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Respiratory rate</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(RR, in room air) (relative and absolute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Retraction, Coughing</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Lab values</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(GOT, Creatinine, gGT, blood count, differential, LDH, potassium, steady state drug level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Oxygen demand</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>in room air, on Os-supplement or O2 flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of QoL</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(PedsQl™ generic and chILD specific module)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Health economics</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>specific questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Overall survival</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>death or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Weight to Height ratio</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Weight measured in kg and Height measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amounts of Steroid equivalents</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Clinical course of lung disease (since last visit): Healthy/ Sick-better/ Sick-same/ Sick-worse/ Patient died</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of x-ray</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>if x-ray were done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pO2, pCO2</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(capillary, in room air)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pulmonary exacerbation</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>(since last visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Forced vital capacity</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>measured by spirometry or bodyplethysmography; If &gt; 5y old (If a child ≤ 5 years is already able to perform the listed investigations (spirometry or bodyplethysmography), these should also be performed and documented at the discretion of the investigator.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of abnormal changes in Electrocardiographie (ECG)</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>measured on start and end of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 6 minute walking distance (6MWT) (in meter)</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>O2-saturation will be measured before and after 6MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Borg Scale</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Measured after 6MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with ophthalmologic abnormalities</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>Ophthalmologic review on start and end of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment related advers events</measure>
    <time_frame>Start HCQ block: 28 days; Stop HCQ block: 84 days</time_frame>
    <description>measured on each visit</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Diffuse Parenchymal Lung Disease</condition>
  <condition>Children´s Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Start HCQ block Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Start HCQ block Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop HCQ block Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop HCQ block Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive Placebo for 3 months and will be followed up for additional 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine sulfate</intervention_name>
    <description>Apply drug to modify lysosomal pH</description>
    <arm_group_label>Start HCQ block Verum</arm_group_label>
    <arm_group_label>Stop HCQ block Verum</arm_group_label>
    <other_name>Quensyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Apply Placebo not to modify lysosomal pH</description>
    <arm_group_label>Start HCQ block Placebo</arm_group_label>
    <arm_group_label>Stop HCQ block Placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients should be clinically stable during baseline (between Visit 1 and 2) for
             inclusion into the study

               1. To determine this, attending physicians can use SpO2 in room air for patients on
                  room air or on O2-supplement; the absolute difference on SpO2 is expected not to
                  be ≥ 5% between Visit 1 and 2. For patients on respiratory support, the summary
                  key parameters should not change ≥ 20% between Visit 1 and 2 and

               2. No major changes in other medications between Visit 1 and 2

          2. Mature newborn ≥ 37 weeks of gestation, age ≥ 3 wks and &lt;2y or Infants and children
             (≥2y and &lt; 18y) or Adults (≥18 and ≤30y) or Previously preterm (≤ 37 weeks of
             gestation) babies or children and adults of all ages if chILD genetically diagnosed
             (see inclusion criterion 3.)

          3. Diagnosis of chronic (≥ 3 wks of duration) diffuse parenchymal lung disease (DPLD =
             chILD), defined in at least one of the following ways:

               1. chILD genetically diagnosed Surfactant dysfunction disorders including patients
                  with mutations in SFTPC, SFTPB, ABCA3, TTF1 (Nkx2-1), further extremely rare
                  entities with specific mutations, for example in TBX4, NPC2, NPC1, NPB, COPA,
                  LRBA and other genes. In this case, also previously preterm (≤ 37 weeks of
                  gestation) babies or children and adults of all ages can be included into the
                  study.

               2. chILD histologically diagnosed

                    -  Chronic pneumonitis of infancy (CPI)

                    -  Desquamative interstitial pneumonia (DIP)

                    -  Lipoid pneumonitis / Cholesterol pneumonia

                    -  Nonspecific interstitial pneumonia (NSIP)

                    -  PAP after the exclusion of mutations in GMCSF-Ra/b and GMCSF autoantibodies*

                    -  Usual interstitial pneumonia (UIP)

                    -  Follicular bronchitis/bronchiolitis/Lymphocytic interstitial pneumonia (LIP)

                    -  Storage disease with primary pulmonary involvement (e.g. Niemann Pick)

                    -  Hermansky-Pudlak Syndrome

                    -  Idiopathic pulmonary haemorrhage (haemosiderosis)*

                    -  Other histology diagnosing chILD, in particular combination of the above
                       pattern, but not exclusively

          4. Start block: no HCQ treatment in the last 12 weeks Stop block: stable HCQ treatment
             for at least the last 12 weeks

          5. Ability of subject or/and legal representatives to understand character and individual
             consequences of clinical trial.

          6. Signed and dated informed consent of the subject (if subject has the ability) and the
             representatives (of underaged children) must be available before start of any specific
             trial procedures.

        (*may be diagnosed in the absence of a lung biopsy by characteristic lung lavage cytology
        (PAS stain, Fe stain), CT pattern or autoantibodies (gliadin, endomysium; cANCA) and
        clinical course.)

        Exclusion criteria:

        Subjects presenting with any of the following criteria will not be included in the trial:

          -  chILD primarily related to developmental disorders

          -  chILD primarily related to growth abnormalities reflecting deficient alveolarisation

          -  chILD related to chronic aspiration

          -  chILD related to immunodeficiency

          -  chILD related to abnormalities in lung vessel structure

          -  chILD related to organ transplantation/organ rejection/GvHD

          -  chILD related to recurrent infections

          -  Acute severe infectious exacerbations

          -  Known hypersensitivity to HCQ, or other ingredients of the tablets
             (lactose-monohydrate, povidone, maize starch, magnesium stearate, hypromellose,
             macrogol or titanium dioxide (E 171), silicon dioxide or mannitol), to
             sucrose-octaacetate or sodium saccharine.

          -  Proven retinopathy or maculopathy

          -  Glucose-6-phosphate-dehydrogenase deficiency resulting in favism or hemolytic anemia

          -  Myasthenia gravis

          -  Hematopoetic disorders

          -  Pregnancy and lactation (Women with childbearing potential have to practice a
             medically accepted contraception during trial and till three months after the end of
             the treatment with HCQ, and a negative pregnancy test (serum or urine) should be
             existent on Visit 1, if girls of childbearing age and only if sexual relations are
             known or probable. It is at the discretion and responsibility of the attending
             physician to decide, whether a pregnancy test is necessary or not. Reliable
             contraception are systematic contraceptives (oral, implant, injection). Women that are
             sterile by surgery can participate in the trial. At the discretion of the
             investigator, sexual abstinence is also accepted as contraceptive method. Girls after
             menarche have to receive a counselling about birth control methods in presence of at
             least one parent, which has to be documented in the patient notes.

          -  Participation in other clinical trials during the present clinical trial or not beyond
             the time of 4 half-lives of the medication used, at least one week.

          -  Hereditary galactose intolerance, lactase deficiency or glucose-galactose-
             malabsorption

          -  Renal insufficiency at screening, defined as glomerular filtration rate (GFR)

               -  &lt; 40 mL/min/1.73 m2 in patients age 3 to 8 weeks

               -  &lt; 60 mL/min/1.73 m2 in patients ≥ 8 weeks of age (KDIGO guideline 2012, K/DOQI
                  guideline 2002)

          -  Liver disease, gastrointestinal disorder, haematological disorder, epilepsy or other
             neurological disorder, psoriasis, porphyria at the discretion of the treating
             physician

          -  Simultaneous prescription of other potentially nephrotoxic or hepatotoxic medication
             at the discretion of the treating physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians-University Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elias Seidl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians University Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Griese, Prof., MD</last_name>
    <phone>+49 (0) 89 4400</phone>
    <phone_ext>57870</phone_ext>
    <email>Matthias.Griese@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elias Seidl, MD</last_name>
    <phone>+49 (0) 89 4400</phone>
    <phone_ext>57871</phone_ext>
    <email>Elias.Seidl@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendmedizin Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winfried Baden, MD</last_name>
      <phone>+49 (0) 7071 29</phone>
      <phone_ext>84712</phone_ext>
      <email>winfried.baden@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Griese, Prof., MD</last_name>
      <phone>+49 (0) 89 4400</phone>
      <phone_ext>57870</phone_ext>
      <email>matthias.griese@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Elias Seidl, MD</last_name>
      <phone>+49 (0) 89 4400</phone>
      <phone_ext>57870</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Zielen, Prof., MD</last_name>
      <phone>+49 (0) 69 6301</phone>
      <phone_ext>83063</phone_ext>
      <email>stefan.zielen@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Nährlich, MD</last_name>
      <phone>+49 (0) 641 9855</phone>
      <phone_ext>7620</phone_ext>
      <email>lutz.naehrlich@paediat.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Schwerk, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
      <email>schwerk.nicolaus@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Wetzke, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Joseph- und St. Elisabeth Hospital gGmbH</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cordula Koerner-Rettberg, MD</last_name>
      <phone>+49 (0) 234 509</phone>
      <phone_ext>6605</phone_ext>
      <email>Cordula.Koerner-Rettberg@klinikum-bochum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Essen, Pädiatrische Pneumologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Stehling, MD</last_name>
      <phone>+49 (0) 201 723</phone>
      <phone_ext>3350</phone_ext>
      <email>florian.stehling@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Uwe Mellies, PD, MD</last_name>
      <phone>+49 (0) 201 723</phone>
      <phone_ext>3350</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freerk Prenzel, MD</last_name>
      <phone>+49 (0) 341 9726</phone>
      <phone_ext>838</phone_ext>
      <email>freerk.prenzel@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Berlin, Klinik für Pädiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Mehl, MD</last_name>
      <phone>+49 (0) 30 4505</phone>
      <phone_ext>66552</phone_ext>
      <email>anne.mehl@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Susanne G. Lau, Prof., MD</last_name>
      <phone>+49 (0) 30 4505</phone>
      <phone_ext>66552</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Matthias Griese</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

